JMP Securities reiterates K2M's 'buy' rating: 4 things to know

Spinal Tech

On June 3, JMP Securities analyst David Turkaly restated K2M's "buy" rating, according to Analyst Ratings.

Here are four things to know:

 

1. Mr. Turkaly set a $22 price target on K2M shares.

 

2. Last Friday, K2M shares closed at $13.81.

 

3. Analysts have a consensus rating of "strong buy" on K2M shares. Their average price target is $21.50.

 

4. On May 23, Needham analysts increased K2M's rating to "buy," and set a $21 price target.

 

More articles on devices:
Medtronic, K2M, J&J & more: 15 key notes
3 emerging trends that could impact the global spinal implants market
Global SCS market to grow to 2028: 5 insights

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers